Bulk Manufacturer of Controlled Substances Application: Curia Wisconsin, Inc., 60499-60500 [2023-18923]
Download as PDF
<![CDATA[
60499
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 2, 2023. Such
persons may also file a written request
for a hearing on the application on or
before October 2, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 13, 2023, Catalent
CTS, LLC, 10245 Hickman Mills Drive,
Kansas City, Missouri 64137–1418,
applied to be registered as an importer
of the following basic class(es) of
controlled substance(s):
lotter on DSK11XQN23PROD with NOTICES1
Controlled substance
Gamma Hydroxybutyric
Acid.
Marihuana Extract ...........
Marihuana Extract ...........
Tetrahydrocannabinols ....
Drug
code
Schedule
2010
I
7350
7360
7370
I
I
I
The company plans to import the
listed controlled substances as dosage
unit products for clinical trial studies.
In reference to drug codes 7370
(Tetrahydrocannabinols), the company
plans to import a synthetic
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
tetrahydrocannabinol. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–18919 Filed 8–31–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on August 15, 2023, Fisher
Clinical Services, Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106–
9032, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
Controlled substance
Drug
code
Schedule
7437
7350
1724
9220
9668
9780
I
I
II
II
II
II
[Docket No. DEA–1253]
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Fisher Clinical Services, Inc.,
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 2, 2023. Such
persons may also file a written request
for a hearing on the application on or
before October 2, 2023.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
SUMMARY:
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Psilocybin ........................
Marihuana Extract ...........
Methylphenidate ..............
Levorphanol .....................
Noroxymorphone .............
Tapentadol ......................
The company plans to import the
listed controlled substances for clinical
trials only. No other activities for these
drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–18922 Filed 8–31–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1251]
Bulk Manufacturer of Controlled
Substances Application: Curia
Wisconsin, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Curia Wisconsin, Inc has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
SUMMARY:
E:\FR\FM\01SEN1.SGM
01SEN1
60500
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 31, 2023. Such
persons may also file a written request
for a hearing on the application on or
before October 31, 2023.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
ADDRESSES:
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
In
accordance with 21 CFR 1301.33(a), this
is notice that on August 3, 2023, Curia
Wisconsin, Inc., 870 Badger Circle,
Grafton, Wisconsin 53024–0000,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Lysergic acid diethylamide .....................................................................................................................................................
Tetrahydrocannabinols ...........................................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine .................................................................................................................................
3,4-Methylenedioxyamphetamine ...........................................................................................................................................
3,4-Methylenedioxymethamphetamine ...................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine ........................................................................................................................................
Dimethyltryptamine .................................................................................................................................................................
Psilocybin ...............................................................................................................................................................................
Psilocyn ..................................................................................................................................................................................
Methylphenidate .....................................................................................................................................................................
Nabilone .................................................................................................................................................................................
ANPP (4-Anilino-N-phenethyl-4-piperidine) ............................................................................................................................
Noroxymorphone ....................................................................................................................................................................
Fentanyl ..................................................................................................................................................................................
The company plans to bulk
manufacture the listed controlled
substances for the purpose of analytical
reference standards or for sale to its
customers. In reference to the drug code
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture as
synthetic. No other activities for these
drug codes are authorized for this
registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023–18923 Filed 8–31–23; 8:45 am]
BILLING CODE P
DEPARTMENT OF LABOR
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Radiation
Sampling and Exposure Records
Notice of availability; request
for comments.
ACTION:
The Department of Labor
(DOL) is submitting this Bureau of Labor
Statistics (BLS)-sponsored information
collection request (ICR) to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995
(PRA). Public comments on the ICR are
invited.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
The OMB will consider all
written comments that the agency
receives on or before October 2, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Comments are invited on: (1) whether
the collection of information is
necessary for the proper performance of
the functions of the Department,
including whether the information will
have practical utility; (2) the accuracy of
the agency’s estimates of the burden and
cost of the collection of information,
including the validity of the
methodology and assumptions used; (3)
ways to enhance the quality, utility and
clarity of the information collection; and
(4) ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
automated collection techniques or
other forms of information technology.
FOR FURTHER INFORMATION CONTACT:
Michael Howell by telephone at 202–
693–6782, or by email at DOL_PRA_
PUBLIC@dol.gov.
SUPPLEMENTARY INFORMATION: MSHA is
required to-issue regulations requiring
operators to maintain accurate records
DATES:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
7315
7370
7392
7400
7405
7431
7435
7437
7438
1724
7379
8333
9668
9801
Schedule
I
I
I
I
I
I
I
I
I
II
II
II
II
II
of employee exposures to potentially
toxic materials or harmful physical
agents which are required to be
monitored or measured under any
applicable mandatory health or safety
standard promulgated under this Act.
Airborne radon and radon daughters
exist in every uranium mine and in
several other underground mining
commodities. Radon is radioactive gas.
It diffuses into the underground mine
atmosphere through the rock and the
ground water. Radon decays in a series
of steps into other radioactive elements,
which are solids, called radon
daughters. Radon and radon daughters
are invisible and odorless. Decay of
radon and its daughters results in
emissions of alpha energy. For
additional substantive information
about this ICR, see the related notice
published in the Federal Register on
March 21, 2023 (88 FRN 17020).
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless the OMB
approves it and displays a currently
valid OMB Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
display a valid OMB Control Number.
See 5 CFR 1320.5(a) and 1320.6.
Agency: DOL–MSHA.
E:\FR\FM\01SEN1.SGM
01SEN1
]]>Agencies
[Federal Register Volume 88, Number 169 (Friday, September 1, 2023)]
[Notices]
[Pages 60499-60500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18923]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1251]
Bulk Manufacturer of Controlled Substances Application: Curia
Wisconsin, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Curia Wisconsin, Inc has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
[[Page 60500]]
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
October 31, 2023. Such persons may also file a written request for a
hearing on the application on or before October 31, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on August 3, 2023, Curia Wisconsin, Inc., 870 Badger
Circle, Grafton, Wisconsin 53024-0000, applied to be registered as a
bulk manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Lysergic acid diethylamide.................. 7315 I
Tetrahydrocannabinols....................... 7370 I
4-Bromo-2,5-dimethoxyphenethylamine......... 7392 I
3,4-Methylenedioxyamphetamine............... 7400 I
3,4-Methylenedioxymethamphetamine........... 7405 I
5-Methoxy-N-N-dimethyltryptamine............ 7431 I
Dimethyltryptamine.......................... 7435 I
Psilocybin.................................. 7437 I
Psilocyn.................................... 7438 I
Methylphenidate............................. 1724 II
Nabilone.................................... 7379 II
ANPP (4-Anilino-N-phenethyl-4-piperidine)... 8333 II
Noroxymorphone.............................. 9668 II
Fentanyl.................................... 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the purpose of analytical reference standards or for
sale to its customers. In reference to the drug code 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture as
synthetic. No other activities for these drug codes are authorized for
this registration.
Claude Redd,
Acting Deputy Assistant Administrator.
[FR Doc. 2023-18923 Filed 8-31-23; 8:45 am]
BILLING CODE P
